FOXO4
Forkhead box O4 transcription factor — ≠ FOXO4-DRI senolytic peptide.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. FOXO4 is an endogenous Forkhead box O4 transcription factor (protein), not a research peptide sold as a vial. It participates in stress response, differentiation, and p53 interaction / senescence biology. ≠ FOXO4-DRI (synthetic D-retro-inverso senolytic peptide — separate drawer). No small-molecule PubChem peptide CID is used for the native transcription factor in this pack. This drawer marks molecular/biology papers. It is not use advice.
Bottom line
FOXO4 literature here is mechanistic: FOXO4–p53 biophysics, cancer/senescence context, and developmental roles. Do not grade FOXO4 protein biology as evidence that injectable “FOXO4” peptides work in humans. Senolytic intervention claims belong only under the FOXO4-DRI drawer — and even there remain preclinical.
Papers
FOXO4–p53 / senescence mechanism (endogenous TF)
PMID 34954873 — Kim 2022
Tested: biophysical investigation of dual binding surfaces of human transcription factors FOXO4 and p53.
Does not show: human senolytic drug efficacy, or that a gray-market peptide is FOXO4.
PMID 35481640 — Mandal 2022
Tested: FOXO4 interacting with p53 TAD and CRD and inhibiting p53 DNA binding (molecular mechanism).
Does not show: a clinical anti-aging indication.
PMID 21613825 — Zhang 2011
Tested: review of FoxO family members in cancer.
Does not show: injectable FOXO4 peptide therapy.
PMID 23551888 — Vilchez 2013
Tested: FOXO4 necessity for neural differentiation of human embryonic stem cells.
Does not show: consumer neurogenesis claims from peptide vials.
Pointer — senolytic peptide is a different object
PMID 28340339 — Baar 2017
Tested: targeted apoptosis of senescent cells with a FOXO4-directed peptide restoring tissue homeostasis in chemotoxicity/aging models (FOXO4-DRI object).
Does not show: FOXO4 protein itself as a drug; full grading lives in the FOXO4-DRI drawer — listed here only as a cross-link warning.
What is not established
That endogenous FOXO4 transcription-factor papers justify unlabeled “FOXO4” peptide products. Human clinical anti-aging efficacy for FOXO4 modulation outside carefully labeled investigational programs. Equivalence of FOXO4 and FOXO4-DRI. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.